



**MDR-TB: Overcoming Global Resistance**  
**June 16-18, 2009**  
**Bell Harbor International Conference Center**

**Tuesday, June 16, 2009**

---

17:30 – 21:00     **Reception and Opening Dinner – Harbor Dining Room**

Welcome Addresses:     Michael BIRT  
   *Executive Director, Pacific Health Summit*  
   Lee HARTWELL  
   *President and Director, Fred Hutchinson Cancer Research Center*  
   Mark WALPORT  
   *Director, The Wellcome Trust*  
   Tadataka YAMADA  
   *President, Global Health Program, Bill & Melinda Gates Foundation*

Introducer:                 Richard ELLINGS  
   *President, The National Bureau of Asian Research*

Moderator:                 Maria CATTALUI,  
   *Former Secretary-General, International Chamber of Commerce*

Featured Contributors:     Peter PIOT,  
   *Director and Professor, Institute of Global Health, Imperial College*

**Wednesday, June 17, 2009**

---

7:00                         **Registration Opens and Breakfast Available**

8:00 – 8:30               **State of the Science Address**

Introducer:                 Jeremiah CHAKAYA  
   *Chief Research Officer, Kenya Medical Research Institute*

Speaker:                     Anthony FAUCI  
   *Director, National Institute of Allergy and Infectious Diseases,*  
   *National Institutes of Health*

8:30 – 10:15             **Opening Plenary Panel Session**

**New leadership and dynamic innovation: Moving beyond the unreasonable status quo**

How can high-burden emerging economies lead the effort to stop MDR-TB? How do we translate and implement the findings from the April Beijing meeting into actionable policy? How can political will leverage new commitments to catalyze public-private innovation?

Introducers:                 Chris VIEHBACHER  
   *Chief Executive Officer, sanofi-aventis*  
   Depei LIU  
   *President, Chinese Academy of Medical Sciences*

Moderator: Peter SINGER  
*Professor of Medicine, Sun Life Financial Chair in Bioethics and Director, McLaughlin-Rotman Centre for Global Health, University Health Network, University of Toronto*

Panelists: Maharaj K. BHAN  
*Secretary, Department of Biotechnology, India*  
Carlos Augusto Grabois GADELHA  
*Vice President, Health Production and Innovation, Fiocruz*  
Kewen JIN  
*General Manager, Charles River Laboratories*  
Yogan PILLAY  
*Deputy Director-General, Strategic Health Programs, National Department of Health, South Africa*  
Mphu RAMATLAPENG  
*Minister, Ministry of Health, Lesotho*  
Tadataka YAMADA  
*President, Global Health Program, Bill & Melinda Gates Foundation*

10:15 – 10:45 **Break**

10:45 – 12:15 **Plenary Panel Session II: Why should industry be fully engaged in the battle?**  
How do we influence and accelerate research and development for new drugs, vaccines, and diagnostics?  
What is the untapped market for these tools?

Introducer: Mark HARRINGTON  
*Executive Director & Co-Founder, Treatment Action Group*

Moderator: Mark WALPORT  
*Director, The Wellcome Trust*

Panelists: Wayne PISANO  
*President and Chief Executive Officer, sanofi pasteur*  
Peer SCHATZ  
*Chief Executive Officer, Qiagen*  
Melvin SPIGELMAN  
*President and Chief Executive Officer, Global Alliance for TB Drug Development*  
Paul STOFFELS  
*Company Group Chairman, Global Research and Development, Pharmaceuticals, Johnson & Johnson*

12:15 – 12:30 **Break**

12:30 – 14:00 **Working Lunch – Harbor Dining Room**  
**What does the TB battle really look like? Stories from the front lines**  
How do we elevate this forgotten disease alongside HIV and Malaria, as well as learn from efforts to address those challenges? What do proposed solutions mean for people coping with TB and MDR-TB every day? How do we protect healthcare workers and immuno-compromised individuals in high-burden countries and help prevent the spread of MDR-TB in the first place?

Introducer: James NACHTWEY  
*Documentary Photographer, James Nachtwey Studio*

Moderator: Paul FARMER  
*Co-Founding Director, Partners In Health*

Commentators: Jaime BAYONA  
*Director-General, Socio En Salud Sucursal, Peru*  
Bobby JOHN  
*President, Global Health Advocates*  
Thelma TUPASI  
*Executive Director, Tropical Disease Foundation*  
Carol NYIRENDA  
*National Coordinator, Community Initiative for TB, HIV/AIDS & Malaria*

14:00 – 14:30 **Break**

14:30 – 16:00 **Plenary Panel Session III**

**Driving innovation: Compelling partnerships between global health and industry**

How can industry, policymakers, and civil society around the world work together to prevent and overcome MDR-TB? How do we build and strengthen the case for global partnership that will create the best outcomes for patients? How can policy incentivize greater industry engagement? What can non-health companies teach us about effective innovation, and how can they help fill implementation and delivery gaps?

Introducer: Peter SMALL  
*Senior Program Officer, Infectious Disease Division & Team Leader for Tuberculosis, Bill & Melinda Gates Foundation*

Moderator: Maria CATTUI  
*Former Secretary-General, International Chamber of Commerce*

Panelists: Michael BARBER  
*Chief Technology Officer, GE Healthcare*  
Patrizia CARLEVARO  
*Head of International Aid Unit, Eli Lilly and Company*  
Marcos ESPINAL  
*Executive Secretary, Stop TB Partnership Secretariat*  
Giorgio ROSCIGNO  
*Chief Executive Officer, FIND*  
Jerry SADOFF  
*President and Chief Executive Officer, Aeras Global TB Vaccine Foundation*  
Peter SMALL  
*Senior Program Officer, Infectious Disease Division & Team Leader for Tuberculosis, Bill & Melinda Gates Foundation*

16:00 – 16:30 **Break**

16:30 – 18:00 **Plenary Panel Session IV**

**Effective global health delivery—How does it work? How should it work?**

What is the ideal basic structure of a coordinated prevention and treatment approach to MDR-TB? How do we deliver essential treatments and services to the people who need it most? What about the way we deliver care needs to change? How can policy and industry work together to facilitate uptake and scale-up of new technologies in the countries that need them most? How do we balance the need for new vaccines, drugs, and diagnostics with the need for adequate infrastructure and quality and safety control?

Introducer: Yu WANG  
*Director, China Center for Disease Control and Prevention*

Moderator: Nigel CRISP  
*Independent Member, UK House of Lords*

Panelists: Edward COX  
*Director, Office of Antimicrobial Products, U.S. Food and Drug Administration*  
David FLEMING  
*Director and Health Officer, Public Health, Seattle & King County*  
Peter NEUPERT  
*Corporate Vice President, Health Strategy, Microsoft Corporation*  
Mario RAVIGLIONE  
*Director, Stop TB Department, World Health Organization*  
Yu WANG  
*Director, China Center for Disease Control and Prevention*

18:00 – 20:00 **Reception – Harbor Dining Room**



Laurie GARRETT  
*Senior Fellow for Global Health, Council on Foreign Relations*  
Andrew JACK  
*Pharmaceuticals Correspondent, Financial Times*  
Andrew SPEAKER

14:30 – 16:30    **Post Summit Workshop**

**Progress and challenges in addressing the fixed dose combinations (FDC) bottleneck in TB control:  
Country experiences and lessons to build momentum – *Sound Conference Room***

Chair:                    Michael KIMERLING  
*Senior Program Officer, Global Health Program, Bill & Melinda Gates Foundation*